Comparing SG&A Expenses: Catalent, Inc. vs Bausch Health Companies Inc. Trends and Insights

SG&A Expenses: A Tale of Two Companies

In the competitive landscape of the pharmaceutical and biotechnology sectors, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Catalent, Inc. and Bausch Health Companies Inc. from 2014 to 2023.

Catalent, Inc.

Catalent has shown a consistent upward trend in SG&A expenses, growing by approximately 180% over the decade. This increase reflects their strategic investments in expanding operations and enhancing market presence. By 2023, their expenses reached around $835 million, a significant rise from $335 million in 2014.

Bausch Health Companies Inc.

Conversely, Bausch Health's SG&A expenses have fluctuated, peaking in 2023 at nearly $2.92 billion, a 44% increase from 2014. This volatility may indicate strategic shifts or market challenges. Notably, data for 2024 is missing, suggesting potential changes in reporting or financial strategy.